A mathematical model of combination therapy using the EGFR signaling network

BioSystems

Volumn 80, Issue 1, 2005, Pages 57-69

  Araujo, R P ^a   Petricoin, E F ^b   Liotta, L A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cancer treatment; Combination therapy; EGFR network; Kinase inhibitors; Signal transduction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOTRANSFERASE INHIBITOR;

CANCER; INHIBITION; NUMERICAL MODEL;

ARTICLE; CANCER THERAPY; MATHEMATICAL MODEL; SIGNAL TRANSDUCTION;

EID: 14644403608     PISSN: 03032647     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biosystems.2004.10.002     Document Type: Article

References (17)

1. P.M. Harari, and S.-M. Huang Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? Int. J. Radiat. Oncol. Biol. Phys. 58 3 2004 976 983
2. R. Heinrich, B.G. Neel, and T.A. Rapoport Mathematical models of protein kinase signal transduction Mol. Cell 9 2002 957 970
3. B.N. Kholodenko, O.V. Demin, G. Moehren, and J.B. Hoek Quantification of short term signaling by the epidermal growth factor receptor J. Biol. Chem. 274 1999 30169 30181
4. F. Koizumi, F. Kanzawa, Y. Ueda, Y. Koh, S. Tsukiyama, F. Taguchi, T. Tamura, N. Saijo, and K. Nishio Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase i inhibitor CPT-11 (irinotecan) in human colorectal cancer cells Int. J. Cancer 108 2004 464 472
5. C.J. Langer Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC Int. J. Radiat. Oncol. Biol. Phys. 58 3 2004 991 1002
6. L.A. Liotta, E.C. Kohn, and E.F. Petricoin Clinical proteomics: personalised molecular medicine J. Am. Med. Assoc. 286 18 2001 2211 2214
7. N.I. Markevich, J.B. Hoek, and B.N. Kholodenko Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades J. Cell Biol. 164 3 2004 353 359
8. M. Mimeault, N. Pommery, and J.-P. Henichart Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase A inhibitors in human prostatic cancer cell lines Int. J. Cancer 106 2003 116 124
9. M.E.M. Noble, J.A. Endicott, and L.N. Johnson Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1804
10. S.B. Noonberg, and C.C. Benz Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents Drugs 59 4 2000 753 767
11. D. Raben, B.A. Helfrich, D. Chan, G. Johnson, and P.A. Bunn ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer Semin. Oncol. 29 1S4 2002 37 46
12. M. Ranson ZD1839 (Iressa™): for more than just non-small cell lung cancer Oncologist 7 2002 16 24
13. E. Raymond, S. Faivre, and J.P. Armand Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 S1 2000 15 23
14. G. Tortora, R. Caputo, V. Damiano, G. Fontanini, D. Melisi, B.M. Veneziani, F. Zunino, A.R. Bianco, and F. Ciardiello Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor iressa causes cooperative antitumor and antiangiogenic activity Clin. Cancer Res. 7 2001 4156 4163
15. A.S. Tsao, and R.S. Herbst Factors that determine response to EGFR inhibitors Signal 4 4 2003 4 9
16. J.J. Tyson, K.C. Chen, and B. Novak Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell Curr. Opin. Cell Biol. 15 2003 221 231
17. H.S. Wiley, S.Y. Shvartsman, and D.A. Lauffenburger Computational modeling of the EGF-receptor system: a paradigm for systems biology Trends Cell Biol. 13 1 2003 43 50